Kinomics - Structural biology and chemogenomics of kinase inhibitors and targets

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1697, Issue 1-2, 2004, Pages 243-257

  Vieth, Michal ^a   Higgs, Richard E ^a   Robertson, Daniel H ^a   Shapiro, Michael ^a   Gragg, Ellen A ^a   Hemmerle, Horst ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

ABL1; ANP; ATP binding site; Binding fingerprint; CDC2; CDC2L2; Cell division cycle 2; Chemogenomics; Kinase similarity; Phosphoaminophosphonic acid adenylate ester; Protein kinase; SAR similarity; v abl Abelson murine leukemia viral oncogene homologue 1

Indexed keywords

PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; TOXIC SUBSTANCE;

CONFERENCE PAPER; GENOMICS; MOLECULE; PREDICTION; PRIORITY JOURNAL; PROTEIN TARGETING; SEQUENCE HOMOLOGY; STEREOCHEMISTRY;

ADENOSINE TRIPHOSPHATE; BINDING SITES; CLUSTER ANALYSIS; COMPUTATIONAL BIOLOGY; DATABASES, FACTUAL; DRUG DESIGN; ENZYME INHIBITORS; GENOMICS; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PHOSPHOTRANSFERASES; STRUCTURE-ACTIVITY RELATIONSHIP;

MURINAE;

EID: 1542358841     PISSN: 15709639     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbapap.2003.11.028     Document Type: Conference Paper

References (109)

1. Taylor S.S., Radzio-Andzelm E. Protein kinase inhibition: natural and synthetic variations on a theme. Curr. Opin. Chem. Biol. 1:1997;219-226.
2. Bossemeyer D. Protein kinases-structure and function. FEBS Lett. 369:1995;57-61.
3. Levitzki A. Protein kinase inhibitors as a therapeutic modality. Acc. Chem. Res. 36:2003;462-469.
4. Michaelis M.L. Drugs targeting alzheimer's disease: some things old and some things new. J. Pharmacol. Exp. Ther. 304:2003;897-904.
5. Fabbro D., Garcia-Echeverria C.G. Targeting protein kinases in cancer therapy. Curr. Opin. Drug Discov. Dev. 5:2002;701-712.
6. Fabbro D., Ruetz S., Buchdunger E., Cowan-Jacob S.W., Fendrich G., Liebetanz J., Mestan J., O'Reilly T., Traxler P., Chaudhuri B., Fretz H., Zimmermann J., Meyer T., Caravatti G., Furet P., Manley P.W. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacol. Ther. 93:2002;79-98.
7. Gabriele A., King G.L. Protein kinase c inhibitors in the treatment and prevention of diabetic complications. Curr. Opin. Endocrinol. Diabetes. 8:2001;197-204.
8. Myers M.R., He W., Hulme C. Inhibitors of tyrosine kinases involved in inflammation and autoimmune disease. Curr. Pharm. Des. 3:1997;473-502.
9. Kim J.A. Targeted therapies for the treatment of cancer. Am. J. Surg. 186:2003;264-268.
10. Kumar C.C., Madison V. Drugs targeted against protein kinases. [erratum to document cited in ca137:56743]. Exp. Opin. Emerg. Drugs. 7:2002;207.
11. Muhsin M., Graham J., Kirkpatrick P. Fresh from the pipeline: Gefitinib. Nat. Rev., Cancer. 3:2003;556-557.
12. Asano T., Ikegaki I., Satoh S.-I., Seto M., Sasaki Y. A protein kinase inhibitor, fasudil (at-877): a novel approach to signal transduction therapy. Card. Drug Rev. 16:1998;76-87.
13. NIH International Consortium Completes Human Genome Project. 2003;National Institute of Health, Bethesda, MD. http://www.genome.gov/11006929.
14. Westbrook J., Feng Z., Chen L., Yang H., Berman Helen M. The protein data bank and structural genomics. Nucleic Acids Res. 31:2003;489-491.
15. Williams D.H., Mitchell T. Latest developments in crystallography and structure-based design of protein kinase inhibitors as drug candidates. Curr. Opin. Pharmacol. 2:2002;567-573.
16. Caron P.R., Mullican M.D., Mashal R.D., Wilson K.P., Su M.S., Murcko M.A. Chemogenomic approaches to drug discovery. Curr. Opin. Chem. Biol. 5:2001;464-470.
17. Jacoby E., Schuffenhauer A., Floersheim P. Chemogenomics knowledge-based strategies in drug discovery. Drug News Perspect. 16:2003;93-102.
18. Vieth M., Brooks H.B., Hamdouchi C., McMillen W., Sawyer J.S., Yingling J.M., Zhang F. Combining medicinal chemistry with chemogenomic and computer-aided structure-based design in development of novel kinase inhibitors. Cell. Mol. Biol. Lett. 8:2003;566-567.
19. Furness M., Pearson C., Natsoulis G., Engelberg A., Bostian K., Jarnagin K. Chemogenomics for predictive drug assessment. Toxicogenomics. 2003;204-212.
20. Kamano S., Yano S., Dong R.-P. Epidermal growth factor receptor (egfr) tyrosine kinase inhibitor, zd1839 profile. Saibo. 34:2002;170-173.
21. Busse D., Yakes F.M., Lenferink A.E.G., Arteaga C.L. Tyrosine kinase inhibitors: rationale, mechanisms of action, and implications for drug resistance. Sem. Oncol. Nurs. 28:2001;47-55.
22. Naumann T., Matter H. Structural classification of protein kinases using 3d molecular interaction field analysis of their ligand binding sites: target family landscapes. J. Med. Chem. 45:2002;2366-2378.
23. Manning G., Whyte D.B., Martinez R., Hunter T., Sudarsanam S. The protein kinase complement of the human genome. Science. 298:2002;1912-1934.
24. Bridges A.J. Chemical inhibitors of protein kinases. Chem. Rev. 101:2001;2541-2571.
25. Lawrence D.S., Niu J. Protein kinase inhibitors: the tyrosine-specific protein kinase. Pharmacol. Ther. 77:1998;81-114.
26. Wang Z., Canagarajah B.J., Boehm J.C., Kassisa S., Cobb M.H., Young P.R., Abdel-Meguid S., Adams J.L., Goldsmith E.J. Structural basis of inhibitor selectivity in map kinases. Structure. 6:1998;1117-1128.
27. Gum R.J., McLaughlin M.M., Kumar S., Wang Z., Bower M.J., Lee J.C., Adams J.L., Livi G.P., Goldsmith E.J., Young P.R. Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, sb 203580, by alteration of one or more amino acids within the atp binding pocket. J. Biol. Chem. 273:1998;15605-15610.
28. Pruitt K.D., Maglott D.R. Refseq and locuslink: NCBI gene-centered resources. Nucleic Acids Res. 29:2001;137-140.
29. Pruitt K.D., Katz K.S., Sicotte H., Maglott D.R. Introducing refseq and locuslink: curated human genome resources at the NCBI. Trends Genet. 16:2002;44-47.
30. Sugen Structure and Phylogeny of the Protein Kinases. 2002;Salk Institute, La Jolla, CA. http://198.202.68.14/human/kinome/phylogeny.html.
31. G.J. Kleywegt, 990823/7.1.4 ed., Dept. Cell Mol. Biol., Uppsala, Uppsala, (1992-1999).
32. Kauvar L.M., Villar H.O. Deciphering cryptic similarities in protein binding sites. Curr. Opin. Biotechnol. 9:1998;390-394.
33. Kauvar L.M. Affinity fingerprinting: implications for drug discovery. Pharm. News. 3:1996;12-15.
34. Frye S.V. Structure-activity relationship homology (sarah): a conceptual framework for drug discovery in the genomic era. Chem. Biol. 6:1999;R3-R7.
35. Zimmermann J., Buchdunger E., Mett H., Meyer T., Lydon N.B. Potent and selective inhibitors of the abl-kinase: phenylaminopyrimidine (pap) derivatives. Bioorg. Med. Chem. Lett. 7:1997;187-192.
36. Schindler T., Bornmann W., Pellicena P., Miller W.T., Clarkson B., Kuriyan J. Structural mechanism for sti-571 inhibition of abelson tyrosine kinase. Science. 289:2000;1938-1942.
37. Pargellis C., Tong L., Churchill L., Cirillo Pier F., Gilmore T., Graham Anne G., Grob Peter M., Hickey Eugene R., Moss N., Pav S., Regan J. Inhibition of p38 map kinase by utilizing a novel allosteric binding site. Nat. Struct. Biol. 9:2002;268-272.
38. Knighton D.R., Zheng J.H., Ten Eyck L.F., Xuong N.H., Taylor S.S., Sowadski J.M. Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science. 253:1991;414-420.
39. Knighton D.R., Zheng J.H., Ten Eyck L.F., Ashford V.A., Xuong N.H., Taylor S.S., Sowadski J.M. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science. 253:1991;407-414.
40. Gribskov M., Devereux J. Sequence Analysis Primer. 1991;Stockton Press, Madison, WI.
41. Chu S.S., Alegria L.A., Bender S.L., Benedict S.P., Borchardt A.J., Kania R.S., Nambu M.D., Tempczyk-Russell A.M., Sarshar S. PCT Int. Appl., Preparation of Diaminothiazoles for Inhibiting Protein Kinases. 2000;Agouron Pharmaceuticals Inc. USA. 397 pp., Wo0075120.
42. Missbach M., Altmann E., Widler L., Susa M., Buchdunger E., Mett H., Meyer T., Green J. Substituted 5,7-diphenylpyrrolo[2,3-d]pyrimidines: potent inhibitors of the tyrosine kinase c-src. Bioorg. Med. Chem. Lett. 10:2000;945-949.
43. Chong W.K.M., Chu S.S., Duvadie R.R., Li L., Xiao W., Yang Y. PCT Int. Appl., Preparation of 4-Aminothiazole Derivatives as Inhibitors of Cyclin-Dependent Kinases. 1999;Agouron Pharmaceuticals Inc. USA. 172 pp., Wo9921845.
44. Connolly C.J.C., Hamby J.M., Schroeder M.C., Barvian M., Lu G.H., Panek R.L., Amar A., Shen C., Kraker A.J., Fry D.W., Klohs W.D., Doherty A.M. Discovery and structure-activity studies of a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. Bioorg. Med. Chem. Lett. 7:1997;2415-2420.
45. Kim Kyoung S., Kimball S.D., Misra Raj N., Rawlins David B., Hunt John T., Xiao H.-Y., Lu S., Qian L., Han W.-C., Shan W., Mitt T., Cai Z.-W., Poss Michael A., Zhu H., Sack John S., Tokarski John S., Chang Chieh Y., Pavletich N., Kamath A., Humphreys William G., Marathe P., Bursuker I., Kellar Kristen A., Roongta U., Batorsky R., Mulheron Janet G., Bol D., Fairchild Craig R., Lee Francis Y., Webster Kevin R. Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities. J. Med. Chem. 45:2002;3905-3927.
46. Boschelli D.H., Ye F., Wang Y.D., Dutia M., Johnson S.L., Wu B., Miller K., Powell D.W., Yaczko D., Young M., Tischler M., Arndt K., Discafani C., Etienne C., Gibbons J., Grod J., Lucas J., Weber J.M., Boschelli F. Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of src kinase activity. J. Med. Chem. 44:2001;3965-3977.
47. Smith R.A., Barbosa J., Blum C.L., Bobko M.A., Caringal Y.V., Dally R., Johnson J.S., Katz M.E., Kennure N., Kingery-Wood J., Lee W., Lowinger T.B., Lyons J., Marsh V., Rogers D.H., Swartz S., Walling T., Wild H. Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach. Bioorg. Med. Chem. Lett. 11:2001;2775-2778.
48. Tsou H.R., Mamuya N., Johnson B.D., Reich M.F., Gruber B.C., Ye F., Nilakantan R., Shen R., Discafani C., DeBlanc R., Davis R., Koehn F.E., Greenberger L.M., Wang Y.F., Wissner A. 6-substituted-4-(3-bromophenylamino) quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (egfr) and human epidermal growth factor receptor (her-2) tyrosine kinases with enhanced antitumor activity. J. Med. Chem. 44:2001;2719-2734.
49. Schroeder M.C., Hamby J.M., Connolly C.J., Grohar P.J., Winters R.T., Barvian M.R., Moore C.W., Boushelle S.L., Crean S.M., Kraker A.J., Driscoll D.L., Vincent P.W., Elliott W.L., Lu G.H., Batley B.L., Dahring T.K., Major T.C., Panek R.L., Doherty A.M., Showalter H.D. Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity. J. Med. Chem. 44:2001;1915-1926.
50. Sielecki T.M., Johnson T.L., Liu J., Muckelbauer J.K., Grafstrom R.H., Cox S., Boylan J., Burton C.R., Chen H., Smallwood A., Chang C.H., Boisclair M., Benfield P.A., Trainor G.L., Seitz S.P. Quinazolines as cyclin dependent kinase inhibitors. Bioorg. Med. Chem. Lett. 11:2001;1157-1160.
51. Thompson A.M., Connolly C.J., Hamby J.M., Boushelle S., Hartl B.G., Amar A.M., Kraker A.J., Driscoll D.L., Steinkampf R.W., Patmore S.J., Vincent P.W., Roberts B.J., Elliott W.L., Klohs W., Leopold W.R., Showalter H.D., Denny W.A. 3-(3,5-dimethoxyphenyl)-1,6-naphthyridine-2,7-diamines and related 2-urea derivatives are potent and selective inhibitors of the fgf receptor-1 tyrosine kinase. J. Med. Chem. 43:2000;4200-4211.
52. Dumas J., Sibley R., Riedl B., Monahan M.K., Lee W., Lowinger T.B., Redman A.M., Johnson J.S., Kingery-Wood J., Scott W.J., Smith R.A., Bobko M., Schoenleber R., Ranges G.E., Housley T.J., Bhargava A., Wilhelm S.M., Shrikhande A. Discovery of a new class of p38 kinase inhibitors. Bioorg. Med. Chem. Lett. 10:2000;2047-2050.
53. Thompson A.M., Rewcastle G.W., Boushelle S.L., Hartl B.G., Kraker A.J., Lu G.H., Batley B.L., Panek R.L., Showalter H.D., Denny W.A. Synthesis and structure-activity relationships of 7-substituted 3-(2, 6-dichlorophenyl)-1,6- naphthyridin-2(1h)-ones as selective inhibitors of pp60(c-src). J. Med. Chem. 43:2000;3134-3147.
54. Bold G., Altmann K.H., Frei J., Lang M., Manley P.W., Traxler P., Wietfeld B., Bruggen J., Buchdunger E., Cozens R., Ferrari S., Furet P., Hofmann F., Martiny-Baron G., Mestan J., Rosel J., Sills M., Stover D., Acemoglu F., Boss E., Emmenegger R., Lasser L., Masso E., Roth R., Schlachter C., Vetterli W. New anilinophthalazines as potent and orally well absorbed inhibitors of the vegf receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis. J. Med. Chem. 43:2000;2310-2323.
55. Hennequin L.F., Thomas A.P., Johnstone C., Stokes E.S., Ple P.A., Lohmann J.J., Ogilvie D.J., Dukes M., Wedge S.R., Curwen J.O., Kendrew J., Lambert-van der Brempt C. Design and structure-activity relationship of a new class of potent vegf receptor tyrosine kinase inhibitors. J. Med. Chem. 42:1999;5369-5389.
56. Liverton N.J., Butcher J.W., Claiborne C.F., Claremon D.A., Libby B.E., Nguyen K.T., Pitzenberger S.M., Selnick H.G., Smith G.R., Tebben A., Vacca J.P., Varga S.L., Agarwal L., Dancheck K., Forsyth A.J., Fletcher D.S., Frantz B., Hanlon W.A., Harper C.F., Hofsess S.J., Kostura M., Lin J., Luell S., O'Neill E.A., O'Keefe S.J. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase. J. Med. Chem. 42:1999;2180-2190.
57. de Laszlo S.E., Visco D., Agarwal L., Chang L., Chin J., Croft G., Forsyth A., Fletcher D., Frantz B., Hacker C., Hanlon W., Harper C., Kostura M., Li B., Luell S., MacCoss M., Mantlo N., O'Neill E.A., Orevillo C., Pang M., Parsons J., Rolando A., Sahly Y., Sidler K., O'Keefe S.J. Pyrroles and other heterocycles as inhibitors of p38 kinase. Bioorg. Med. Chem. Lett. 8:1998;2689-2694.
58. Boschelli D.H., Wu Z., Klutchko S.R., Showalter H.D., Hamby J.M., Lu G.H., Major T.C., Dahring T.K., Batley B., Panek R.L., Keiser J., Hartl B.G., Kraker A.J., Klohs W.D., Roberts B.J., Patmore S., Elliott W.L., Steinkampf R., Bradford L.A., Hallak H., Doherty A.M. Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8h-pyrido[2,3-d]pyrimidines: identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors. J. Med. Chem. 41:1998;4365-4377.
59. Klutchko S.R., Hamby J.M., Boschelli D.H., Wu Z., Kraker A.J., Amar A.M., Hartl B.G., Shen C., Klohs W.D., Steinkampf R.W., Driscoll D.L., Nelson J.M., Elliott W.L., Roberts B.J., Stoner C.L., Vincent P.W., Dykes D.J., Panek R.L., Lu G.H., Major T.C., Dahring T.K., Hallak H., Bradford L.A., Showalter H.D., Doherty A.M. 2-substituted aminopyrido[2,3-d]pyrimidin-7(8h)-ones. Structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity. J. Med. Chem. 41:1998;3276-3292.
60. Traxler P., Bold G., Frei J., Lang M., Lydon N., Mett H., Buchdunger E., Meyer T., Mueller M., Furet P. Use of a pharmacophore model for the design of egf-r tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines. J. Med. Chem. 40:1997;3601-3616.
61. Traxler P.M., Furet P., Mett H., Buchdunger E., Meyer T., Lydon N. 4-(phenylamino)pyrrolopyrimidines: potent and selective, atp site directed inhibitors of the egf-receptor protein tyrosine kinase. J. Med. Chem. 39:1996;2285-2292.
62. Traxler P., Trinks U., Buchdunger E., Mett H., Meyer T., Muller M., Regenass U., Rosel J., Lydon N. [(Alkylamino)methyl]acrylophenones: potent and selective inhibitors of the epidermal growth factor receptor protein tyrosine kinase. J. Med. Chem. 38:1995;2441-2448.
63. Dow R.L., Chou T.T., Bechle B.M., Goddard C., Larson E.R. Identification of tricyclic analogs related to ellagic acid as potent/selective tyrosine protein kinase inhibitors. J. Med. Chem. 37:1994;2224-2231.
64. Zaharevitz D.W., Gussio R.P., Jalluri R.K., Sausville E.A., Kunick C., Meijer L. U.S. Pat. Appl. Publ., Preparation of Indolobenzazepinones and Related Compounds as Cyclin Dependent Kinase Inhibitors. 2002;. 40 pp., Cont.-in-part of Appl. No. PCT/US99/13579., (USA)., Us2002042412.
65. Hong C.Y., Lee J.H., Park T.S., Kim J.H., Choi S.H., Yoon S.K., Chung H.H., Son H.S., Kim E.E.K., Ro S.G., Jeong S.W., Kim D.M. PCT Int. Appl., Preparation of 3-Hydroxychromen-4-One Cdk Inhibitors for Treatment of Cancer and Other Proliferative Diseases. 2001;LG Chem. Investment Ltd. S. Korea. 103 pp., Wo0183469.
66. Imbach P., Capraro H.-G., Furet P., Mett H., Meyer T., Zimmermann J. Corrigendum to "2,6,9-trisubstituted purines: optimization towards highly potent and selective cdk1 inhibitors" Bioorg. Med. Chem. Lett. 10:2000;1001.
67. Kunick C., Meijer L., Zaharevitz D.W., Gussio R., Jalluri R.K., Sausville E.A. PCT Int. Appl., Preparation of Indolobenzazepinones and Related Compounds as Cyclin Dependent Kinase Inhibitors. 1999;United States of America, Department of Health and Human Services, USA. 116 pp., Wo9965910.
68. Myers M.R., Setzer N.N., Spada A.P., Zulli A.L., Hsu C.-Y.J., Zilberstein A., Johnson S.E., Hook L.E., Jacoski M.V. The preparation and SAR of 4-(anilino), 4-(phenoxy), and 4-(thiophenoxy)-quinazolines: inhibitors of p56lck and egf-r tyrosine kinase activity. Bioorg. Med. Chem. Lett. 7:1997;417-420.
69. Huang C.-K., Wu F.-Y., Ai Y.-X. Polyhydroxylated 3-(n-phenyl) carbamoyl-2-iminochromene derivatives as potent inhibitors of tyrosine kinase p60c-src. Bioorg. Med. Chem. Lett. 5:1995;2423-2428.
70. Kleinschroth J., Hartenstein J., Rudolph C., Schachtele C. Non-glycosidic/non-aminoalkyl-substituted indolocarbazoles as inhibitors of protein kinase c. Bioorg. Med. Chem. Lett. 3:1993;1959-1964.
71. Smaill J.B., Rewcastle G.W., Loo J.A., Greis K.D., Chan O.H., Reyner E.L., Lipka E., Showalter H.D., Vincent P.W., Elliott W.L., Denny W.A. Tyrosine kinase inhibitors: 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d] pyrimidine-6-acrylamides bearing additional solubilizing functions. J. Med. Chem. 43:2000;1380-1397.
72. Schoepfer J., Fretz H., Chaudhuri B., Muller L., Seeber E., Meijer L., Lozach O., Vangrevelinghe E., Furet P. Structure-based design and synthesis of 2-benzylidene-benzofuran-3-ones as flavopiridol mimics. J. Med. Chem. 45:2002;1741-1747.
73. Mahboobi S., Teller S., Pongratz H., Hufsky H., Sellmer A., Botzki A., Uecker A., Beckers T., Baasner S., Schachtele C., Uberall F., Kassack Matthias U., Dove S., Bohmer Frank D. Bis(1h-2-indolyl)methanones as a novel class of inhibitors of the platelet-derived growth factor receptor kinase. J. Med. Chem. 45:2002;1002-1018.
74. Altmann E., Missbach M., Green J., Susa M., Wagenknecht H.A., Widler L. 7-pyrrolidinyl- and 7-piperidinyl-5-aryl-pyrrolo[2,3-d]pyrimidines-potent inhibitors of the tyrosine kinase c-src. Bioorg. Med. Chem. Lett. 11:2001;853-856.
75. Boschelli D.H., Wang Y.D., Ye F., Wu B., Zhang N., Dutia M., Powell D.W., Wissner A., Arndt K., Weber J.M., Boschelli F. Synthesis and src kinase inhibitory activity of a series of 4-phenylamino-3-quinolinecarbonitriles. J. Med. Chem. 44:2001;822-833.
76. Kim K.S., Sack J.S., Tokarski J.S., Qian L., Chao S.T., Leith L., Kelly Y.F., Misra R.N., Hunt J.T., Kimball S.D., Humphreys W.G., Wautlet B.S., Mulheron J.G., Webster K.R. Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: Synthesis and biological effects. J. Med. Chem. 43:2000;4126-4134.
77. Burchat A.F., Calderwood D.J., Hirst G.C., Holman N.J., Johnston D.N., Munschauer R., Rafferty P., Tometzki G.B. Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck ii. Bioorg. Med. Chem. Lett. 10:2000;2171-2174.
78. Arnold L.D., Calderwood D.J., Dixon R.W., Johnston D.N., Kamens J.S., Munschauer R., Rafferty P., Ratnofsky S.E. Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck i. Bioorg. Med. Chem. Lett. 10:2000;2167-2170.
79. Nacro K., Bienfait B., Lee J., Han K.C., Kang J.H., Benzaria S., Lewin N.E., Bhattacharyya D.K., Blumberg P.M., Marquez V.E. Conformationally constrained analogues of diacylglycerol (dag): 16. How much structural complexity is necessary for recognition and high binding affinity to protein kinase c? J. Med. Chem. 43:2000;921-944.
80. Showalter H.D., Bridges A.J., Zhou H., Sercel A.D., McMichael A., Fry D.W. Tyrosine kinase inhibitors: 16. 6,5,6-Tricyclic benzothieno 3, 2-dpyrimidines and pyrimido 5,4-b- and -4,5-bindoles as potent inhibitors of the epidermal growth factor receptor tyrosine kinase. J. Med. Chem. 42:1999;5464-5474.
81. Traxler P., Green J., Mett H., Sequin U., Furet P. Use of a pharmacophore model for the design of egfr tyrosine kinase inhibitors: isoflavones and 3-phenyl-4(1h)-quinolones. J. Med. Chem. 42:1999;1018-1026.
82. Imbach P., Capraro H.G., Furet P., Mett H., Meyer T., Zimmermann J. 2,6,9-Trisubstituted purines: optimization towards highly potent and selective cdk1 inhibitors. Bioorg. Med. Chem. Lett. 9:1999;91-96.
83. Trumpp-Kallmeyer S., Rubin J.R., Humblet C., Hamby J.M., Hollis Showalter H.D. Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors. J. Med. Chem. 41:1998;1752-1763.
84. Palmer B.D., Rewcastle G.W., Thompson A.M., Boyd M., Showalter H.D., Sercel A.D., Fry D.W., Kraker A.J., Denny W.A. Tyrosine kinase inhibitors. 4. Structure-activity relationships among n- and 3-substituted 2,2′- dithiobis(1h-indoles) for in vitro inhibition of receptor and nonreceptor protein tyrosine kinases. J. Med. Chem. 38:1995;58-67.
85. Thompson A.M., Fry D.W., Kraker A.J., Denny W.A. Tyrosine kinase inhibitors. 2. Synthesis of 2,2′-dithiobis(1h-indole-3-alkanamides) and investigation of their inhibitory activity against epidermal growth factor receptor and pp60v-src protein tyrosine kinases. J. Med. Chem. 37:1994;598-609.
86. Gazit A., Osherov N., Posner I., Bar-Sinai A., Gilon C., Levitzki A. Tyrphostins: 3. Structure-activity relationship studies of alpha-substituted benzylidenemalononitrile 5-s-aryltyrphostins. J. Med. Chem. 36:1993;3556-3564.
87. Schow S.R., Mackman R.L., Blum C.L., Brooks E., Horsma A.G., Joly A., Kerwar S.S., Lee G., Shiffman D., Nelson M.G., Wang X., Wick M.M., Zhang X., Lum R.T. Synthesis and activity of 2,6,9-trisubstituted purines. Bioorg. Med. Chem. Lett. 7:1997;2697-2702.
88. Myers M.R., Setzer N.N., Spada A.P., Persons P.E., Ly C.Q., Maguire M.P., Zulli A.L., Cheney D.L., Zilberstein A., Johnson S.E., Franks C.F., Mitchell K.J. The synthesis and sar of new 4-(n-alkyl-n-phenyl)amino-6,7- dimethoxyquinazolines and 4-(n-alkyl-n-phenyl)aminopyrazolo[3,4-d]pyrimidines, inhibitors of csf-1r tyrosine kinase activity. Bioorg. Med. Chem. Lett. 7:1997;421-424.
89. Dow R.L., Bechle B.M., Chou T.T., Goddard C., Larson E.R. Selective inhibition of the tyrosine kinase pp60sre by analogs of 5,10-dihydropyrimido[4, 5-b]quinolin-4(1h)-one. Bioorg. Med. Chem. Lett. 5:1995;1007-1010.
90. Burke T.R. Jr., Ford H., Osherov N., Levitzki A., Stefanova I., Horak I.D., Marquez V.E. Aryl amides of hydroxylated isoquinolines as protein-tyrosine kinase inhibitors. Bioorg. Med. Chem. Lett. 2:1992;1771-1774.
91. Manley P., Furet W.P., Bold G., Bruggen J., Mestan J., Meyer T., Schnell Christian R., Wood J., Haberey M., Huth A., Kruger M., Menrad A., Ottow E., Seidelmann D., Siemeister G., Thierauch K.-H. Anthranilic acid amides: a novel class of antiangiogenic vegf receptor kinase inhibitors. J. Med. Chem. 45:2002;5687-5693.
92. Hennequin Laurent F., Stokes Elaine S.E., Thomas Andrew P., Johnstone C., Ple Patrick A., Ogilvie Donald J., Dukes M., Wedge Stephen R., Kendrew J., Curwen Jon O. Novel 4-anilinoquinazolines with c-7 basic side chains: design and structure activity relationship of a series of potent, orally active, vegf receptor tyrosine kinase inhibitors. J. Med. Chem. 45:2002;1300-1312.
93. Smaill J.B., Showalter H.D., Zhou H., Bridges A.J., McNamara D.J., Fry D.W., Nelson J.M., Sherwood V., Vincent P.W., Roberts B.J., Elliott W.L., Denny W.A. Tyrosine kinase inhibitors: 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor. J. Med. Chem. 44:2001;429-440.
94. Sielecki T.M., Boylan J.F., Benfield P.A., Trainor G.L. Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation. J. Med. Chem. 43:2000;1-18.
95. Wender P.A., Lippa B., Park C.M., Irie K., Nakahara A., Ohigashi H. Selective binding of bryostatin analogues to the cysteine rich domains of protein kinase c isozymes. Bioorg. Med. Chem. Lett. 9:1999;1687-1690.
96. Kuduk S.D., Zheng F.F., Sepp-Lorenzino L., Rosen N., Danishefsky S.J. Synthesis and evaluation of geldanamycin-estradiol hybrids. Bioorg. Med. Chem. Lett. 9:1999;1233-1238.
97. de Laszlo S.E., Hacker C., Li B., Kim D., MacCoss M., Mantlo N., Pivnichny J.V., Colwell L., Koch G.E., Cascieri M.A., Hagmann W.K. Potent, orally absorbed glucagon receptor antagonists. Bioorg. Med. Chem. Lett. 9:1999;641-646.
98. Bullington J.L., Cameron J.C., Davis J.E., Dodd J.H., Harris C.A., Henry J.R., Pellegrino-Gensey J.L., Rupert K.C., Siekierka J.J. The development of novel and selective p56lck tyrosine kinase inhibitors. Bioorg. Med. Chem. Lett. 8:1998;2489-2494.
99. Rewcastle G.W., Murray D.K., Elliott W.L., Fry D.W., Howard C.T., Nelson J.M., Roberts B.J., Vincent P.W., Showalter H.D., Winters R.T., Denny W.A. Tyrosine kinase inhibitors: 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)- pyrido[3,4-d]pyrimidine (pd 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the egf family of growth factors. J. Med. Chem. 41:1998;742-751.
100. Chen H., Boiziau J., Parker F., Mailliet P., Commercon A., Tocque B., LePecq J.B., Roques B.P., Garbay C. Structure-activity relationships in a series of 5-[(2,5-dihydroxybenzyl)amino]salicylate inhibitors of egf-receptor-associated tyrosine kinase: importance of additional hydrophobic aromatic interactions. J. Med. Chem. 37:1994;845-859.
101. Smyth M.S., Stefanova I., Hartmann F., Horak I.D., Osherov N., Levitzki A., Burke T.R. Jr. Non-amine based analogues of lavendustin a as protein-tyrosine kinase inhibitors. J. Med. Chem. 36:1993;3010-3014.
102. Paul R., Hallett W.A., Hanifin J.W., Reich M.F., Johnson B.D., Lenhard R.H., Dusza J.P., Kerwar S.S., Lin Y., Pickett W.C. Preparation of substituted n-phenyl-4-aryl-2-pyrimidinamines as mediator release inhibitors. J. Med. Chem. 36:1993;2716-2725.
103. Gazit A., Osherov N., Posner I., Yaish P., Poradosu E., Gilon C., Levitzki A. Tyrphostins. 2. Heterocyclic and alpha-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of egf receptor and erbb2/neu tyrosine kinases. J. Med. Chem. 34:1991;1896-1907.
104. Cockerill S., Stubberfield C., Stables J., Carter M., Guntrip S., Smith K., McKeown S., Shaw R., Topley P., Thomsen L., Affleck K., Jowett A., Hayes D., Willson M., Woollard P., Spalding D. Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the egfr and c-erbb-2. Bioorg. Med. Chem. Lett. 11:2001;1401-1405.
105. Azam M., Latek Robert R., Daley George Q. Mechanisms of autoinhibition and sti-571/imatinib resistance revealed by mutagenesis of bcr-abl. Cell. 112:2003;831-843.
106. Bernstein F.C., Koetzle T.F., Williams G.J., Meyer E.F. Jr., Brice M.D., Rodgers J.R., Kennard O., Shimanouchi T., Tasumi M. The protein data bank: a computer-based archival file for macromolecular structures. J. Mol. Biol. 112:1977;535-542.
107. Bulmer M.G. Principles of Statistics. 1979;Dover Publications, New York, NY.
108. Shiffman S.S., Reynolds M.F., Young F.W. Introduction to Multidimensional Scaling: Theory, Methods, and Applications. 1981;Academic Press, New York.
109. SAS Institute Jmp (1989-2001), 2003.